Several trials have demonstrated the efficacy of pembrolizumab (a PD-1 inhibitor) in combination with chemotherapy in patients with advanced NSCLC, regardless of tumor PD-L1 expression (7, 8, 14). The gene discussed is CD274; the disease is neoplasm.